Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 75Etoposide 31Daunorubicin 27Filgrastim 24Mitoxantrone 23Idarubicin 23Busulfan 22Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 20fludarabine phosphate 19Gemtuzumab 14tipifarnib 11Antilymphocyte Serum 11Radiotherapy 10Methotrexate 10Cyclosporine 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Azacitidine 9alvocidib 6aldesleukin 6Whole-Body Irradiation 6Vorinostat 6Topotecan 6Tacrolimus 6Bortezomib 6valspodar 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Erythroblastic, Acute × Bromodeoxyuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡